The results showed that MT1B was downregulated in about 87% (26/30) of CRC tumor tissues (Figure 2A); MT1F was downregulated in about 87% (26/30) of CRC tumor tissues (Figure 2B); MT1G was downregulated in about 70% (21/30) of CRC tumor tissues (Figure 2C); MT1H was downregulated in about 77% (23/30) of CRC tumor tissues (Figure 2D); MT1L was downregulated in about 90% (27/30) of CRC tumor tissues (Figure 2E); and MT1X was downregulated in about 80% (24/30) of CRC tumor tissues (Figure 2F). Here, MT1F is linked to neoplasm.